Japanese-based pharmaceutical firm Daiichi Sankyo has begun enrolment in the Phase IIIb ENTRUST-AF PCI clinical trial of edoxaban for the treatment of atrial fibrillation patients who have undergone percutaneous coronary intervention (PCI) with stent placement.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Edoxaban is an oral, once-daily, direct factor Xa inhibitor designed to make the blood thin and minimise its clotting.

The firm plans to enrol 1,500 patients from 200 clinical sites across countries such as Europe, Korea, Taiwan and Ukraine.

The prospective, randomised, open-label, blinded endpoint evaluation parallel-group Phase IIIb trial will assess the efficacy and safety of once-daily edoxaban compared to a vitamin K antagonist, in terms of incidence of major or clinically relevant non-major ISTH-defined bleeding (MCRB).

See Also:

"ENTRUST-AF PCI will add to the growing body of evidence in the Edoxaban Clinical Research Programme,"

Daiichi Sankyo global medical affairs executive director Hans Lanz said: "ENTRUST-AF PCI will add to the growing body of evidence in the Edoxaban Clinical Research Programme, and the results will advance clinicians' understanding of the potential to reduce the risk of bleeding in atrial fibrillation patients undergoing PCI procedures."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial will evaluate edoxaban as part of a dual anti-thrombotic treatment strategy.

The patients will be administered a 12-month antithrombotic regimen of edoxaban in combination with clopidogrel or another P2Y12 antagonist, or a regimen of a vitamin K antagonist in combination with clopidogrel or another P2Y12 antagonist and 1-12 months ASA.

Edoxaban is currently marketed in Japan, the US, South Korea, Hong Kong, Taiwan, as well as European countries such as Switzerland, the UK, Germany, Ireland, the Netherlands, Italy, Spain, Belgium, Austria and Portugal.

Image: Daiichi Sankyo initiates ENTRUST-AF PCI trial of once-daily edoxaban in patients with atrial fibrillation. Photo: courtesy of Daiichi Sankyo Company.